284 related articles for article (PubMed ID: 29596911)
1. Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.
Minari R; Bordi P; La Monica S; Squadrilli A; Leonetti A; Bottarelli L; Azzoni C; Lagrasta CAM; Gnetti L; Campanini N; Petronini PG; Alfieri R; Tiseo M
J Thorac Oncol; 2018 Jun; 13(6):e89-e91. PubMed ID: 29596911
[No Abstract] [Full Text] [Related]
2. Divergent
Rehman M; Kim C; Reuss JE; Kiedrowski LA; Garg RJ; Liu SV
JCO Precis Oncol; 2021 Nov; 5():939-942. PubMed ID: 34994624
[No Abstract] [Full Text] [Related]
3. Emerging EML4-ALK Variant 5 as a Concurrent Resistance Mechanism to Osimertinib in a Patient With EGFR E19del/T790M NSCLC.
Yan Y; Jiang G; Ma W; Li T; Wang L
Clin Lung Cancer; 2020 Nov; 21(6):562-567. PubMed ID: 32622727
[No Abstract] [Full Text] [Related]
4. Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion.
La Monica S; Minari R; Cretella D; Bonelli M; Fumarola C; Cavazzoni A; Galetti M; Digiacomo G; Riccardi F; Petronini PG; Tiseo M; Alfieri R
Target Oncol; 2019 Oct; 14(5):619-626. PubMed ID: 31502118
[TBL] [Abstract][Full Text] [Related]
5. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer.
Gao J; Li HR; Jin C; Jiang JH; Ding JY
Clin Transl Oncol; 2019 Oct; 21(10):1287-1301. PubMed ID: 30864018
[TBL] [Abstract][Full Text] [Related]
6. Challenging BRAF/EGFR co-inhibition in NSCLC using sequential liquid biopsies.
Solassol J; Vendrell JA; Senal R; Audran P; Leenhardt F; Quantin X
Lung Cancer; 2019 Jul; 133():45-47. PubMed ID: 31200827
[TBL] [Abstract][Full Text] [Related]
7. L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.
Bersanelli M; Minari R; Bordi P; Gnetti L; Bozzetti C; Squadrilli A; Lagrasta CA; Bottarelli L; Osipova G; Capelletto E; Mor M; Tiseo M
J Thorac Oncol; 2016 Oct; 11(10):e121-3. PubMed ID: 27257132
[No Abstract] [Full Text] [Related]
8. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer.
Wang Q; Yang S; Wang K; Sun SY
J Hematol Oncol; 2019 Jun; 12(1):63. PubMed ID: 31227004
[TBL] [Abstract][Full Text] [Related]
9. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.
Planchard D; Loriot Y; André F; Gobert A; Auger N; Lacroix L; Soria JC
Ann Oncol; 2015 Oct; 26(10):2073-8. PubMed ID: 26269204
[TBL] [Abstract][Full Text] [Related]
10. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in
Le X; Puri S; Negrao MV; Nilsson MB; Robichaux J; Boyle T; Hicks JK; Lovinger KL; Roarty E; Rinsurongkawong W; Tang M; Sun H; Elamin Y; Lacerda LC; Lewis J; Roth JA; Swisher SG; Lee JJ; William WN; Glisson BS; Zhang J; Papadimitrakopoulou VA; Gray JE; Heymach JV
Clin Cancer Res; 2018 Dec; 24(24):6195-6203. PubMed ID: 30228210
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation.
Okuno T; Arakawa S; Yoshida T; Ohe Y
Lung Cancer; 2020 May; 143():95-96. PubMed ID: 32209253
[No Abstract] [Full Text] [Related]
12. Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.
Meng P; Koopman B; Kok K; Ter Elst A; Schuuring E; van Kempen LC; Timens W; Hiltermann TJN; Groen HJM; van den Berg A; van der Wekken AJ
Lung Cancer; 2020 Aug; 146():358-361. PubMed ID: 32534795
[TBL] [Abstract][Full Text] [Related]
13. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
[TBL] [Abstract][Full Text] [Related]
14. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
[TBL] [Abstract][Full Text] [Related]
15. Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC.
Knebel FH; Bettoni F; Shimada AK; Cruz M; Alessi JV; Negrão MV; Reis LFL; Katz A; Camargo AA
Lung Cancer; 2017 Jun; 108():238-241. PubMed ID: 28625643
[TBL] [Abstract][Full Text] [Related]
16. Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion.
Dagogo-Jack I; Piotrowska Z; Cobb R; Banwait M; Lennerz JK; Hata AN; Digumarthy SR; Sequist LV
J Thorac Oncol; 2019 Oct; 14(10):e226-e228. PubMed ID: 31558234
[No Abstract] [Full Text] [Related]
17. MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib.
Nishiyama A; Takeuchi S; Adachi Y; Otani S; Tanimoto A; Sasaki M; Matsumoto S; Goto K; Yano S
Cancer Sci; 2020 Oct; 111(10):3813-3823. PubMed ID: 32735723
[TBL] [Abstract][Full Text] [Related]
18. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
[TBL] [Abstract][Full Text] [Related]
19. Detecting acquired V-Raf murine sarcoma viral oncogene homolog B1 V600E mutation associated with osimertinib resistance in epidermal growth factor receptor-mutant lung adenocarcinoma: A case report.
Hagihara Y; Suetsugu T; Uto H; Kozono T; Masada Y; Satozono Y; Shinmura M; Koreeda Y; Mizuno K; Inoue H
Respir Investig; 2024 Jan; 62(1):13-15. PubMed ID: 37925883
[TBL] [Abstract][Full Text] [Related]
20. Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC.
Chen K; Zhou F; Shen W; Jiang T; Wu X; Tong X; Shao YW; Qin S; Zhou C
J Thorac Oncol; 2017 Jun; 12(6):e65-e68. PubMed ID: 28093244
[No Abstract] [Full Text] [Related]
[Next] [New Search]
